MacuCLEAR, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.macuclear.com
Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration
Phase 2
- Conditions
- Non-Exudative Age Related Macular Degeneration
- Interventions
- Drug: MC-1101 Vehicle
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- MacuCLEAR, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02127463
- Locations
- 🇺🇸
Rocky Mountain Retina Consultants, Murray, Utah, United States
Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration
Phase 1
Completed
- Conditions
- Nonexudative Age-related Macular Degeneration
- Interventions
- Drug: MC-1101, Placebo
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- MacuCLEAR, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01922128
- Locations
- 🇺🇸
Sall Eye Center, Artesia, California, United States
Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
Phase 2
Terminated
- Conditions
- Nonexudative Age Related Macular Degeneration
- Interventions
- Drug: MC-1101 Vehicle
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- MacuCLEAR, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01601483
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2009-11-13
- Lead Sponsor
- MacuCLEAR, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01013376
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath